Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | GRM5 | P41594 | 5/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.44 |
| ▸ | VNN1 | O95497 | 1/20 | 0.43 |
| ▸ | CCNK | O75909 | 1/20 | 0.42 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.42 |
| ▸ | PDE2A | O00408 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5746703 | 0.95 | KMT2A (0.46) | KMT2AALDH1A1LMNAMEN1GRM5 | |
| SCHEMBL3862788 | 0.95 | KMT2A (0.46) | KMT2AALDH1A1LMNAMEN1GRM5 | |
| SCHEMBL5748631 | 0.87 | ALDH1A1 (0.53) | KMT2AALDH1A1LMNAMEN1GRM5 | |
| SCHEMBL3856964 | 0.87 | ALDH1A1 (0.53) | KMT2AALDH1A1LMNAMEN1GRM5 | |
| SCHEMBL3861456 | 0.87 | ALDH1A1 (0.53) | KMT2AALDH1A1LMNAMEN1GRM5 | |
| SCHEMBL5746899 | 0.87 | ALDH1A1 (0.53) | KMT2AALDH1A1LMNAMEN1GRM5 | |
| SCHEMBL3866086 | 0.87 | NAMPT (0.43) | KMT2AALDH1A1LMNAMEN1VNN1 | |
| SCHEMBL5745597 | 0.86 | KDM5B (0.53) | KMT2AALDH1A1LMNAMEN1GRM5 | |
| SCHEMBL3864624 | 0.86 | KDM5B (0.53) | KMT2AALDH1A1LMNAMEN1GRM5 | |
| SCHEMBL3867365 | 0.84 | ALDH1A1 (0.51) | KMT2AALDH1A1LMNAMEN1GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7592466-B2 | Ureas having antiangiogenic activity | ABBOTT LABORATORIES (US) | 2009-09-22 | — | — | US | claimed |
| EP-1680415-B1 | PYRROLIDINYL UREA DERIVATIVES AS ANGIOGENESIS INHIBITORS | ABBOTT LAB (US) | 2008-12-31 | — | — | EP | claimed |
| US-20060160806-A1 | N-benzyl-N'-{(3R)-1-[(6-methylpyridin-3-yl)carbonyl]pyrrolidin-3-yl}urea | ABBVIE INC. | 2006-07-20 | — | — | US | claimed |
| US-7592466-B2 | Ureas having antiangiogenic activity | ABBOTT LABORATORIES (US) | 2009-09-22 | — | — | US | disclosed |
| EP-1680415-B1 | PYRROLIDINYL UREA DERIVATIVES AS ANGIOGENESIS INHIBITORS | ABBOTT LAB (US) | 2008-12-31 | — | — | EP | disclosed |
| US-20060160806-A1 | N-benzyl-N'-{(3R)-1-[(6-methylpyridin-3-yl)carbonyl]pyrrolidin-3-yl}urea | ABBVIE INC. | 2006-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160806-A1 | N-benzyl-N'-{(3R)-1-[(6-methylpyridin-3-yl)carbonyl]pyrrolidin-3-yl}urea | FLT4, FLT1, KDR | KMT2A 4101/4885ALDH1A1 1710/4885LMNA 2101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.